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A B S T R A C T
Purpose
To provide new information on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs)
after four cycles of etoposide and cisplatin (EPX4) or three or four cycles of bleomycin, etoposide,
cisplatin (BEPX3/BEPX4).
Methods
Nine hundred ﬁfty-two TCSs . 1 year postchemotherapy underwent physical examination and
completed a questionnaire. Multinomial logistic regression estimated AHOs odds ratios (ORs) in
relation to age, cumulative cisplatin and/or bleomycin dose, time since chemotherapy, socio-
demographic factors, and health behaviors.
Results
Median age at evaluation was 37 years; median time since chemotherapy was 4.3 years. Che-
motherapy consisted largely of BEPX3 (38.2%), EPX4 (30.9%), and BEPX4 (17.9%). None, one to
two, three to four, or ﬁve or more AHOs were reported by 20.4%, 42.0%, 25.1%, and 12.5% of
TCSs, respectively. Median number after EPX4 or BEPX3 was two (range, zero to nine and zero to
11, respectively; P. .05) and two (range, zero to 10) after BEPX4.When comparing individual AHOs
for EPX4 versus BEPX3, Raynaud phenomenon (11.6% v 21.4%; P , .01), peripheral neuropathy
(29.2% v 21.4%; P = .02), and obesity (25.5% v 33.0%; P = .04) differed. Larger cumulative
bleomycin doses (OR, 1.44 per 90,000 IU) were signiﬁcantly associated with ﬁve or more AHOs.
Increasing age was a signiﬁcant risk factor for one to two, three to four, or ﬁve or more AHOs versus
zero AHOs (OR, 1.22, 1.50, and 1.87 per 5 years, respectively; P , .01); vigorous physical activity
was protective (OR, 0.62, 0.51, and 0.41, respectively; P , .05). Signiﬁcant risk factors for three to
four and ﬁve or more AHOs included current (OR, 3.05 and 3.73) or former (OR, 1.61 and 1.76)
smoking (P, .05). Self-reported health was excellent/very good in 59.9% of TCSs but decreased as
AHOs increased (P , .001).
Conclusion
Numbers of AHOs after EPX4 or BEPX3 appear similar, withmedian follow-up of 4.3 years. A healthy
lifestyle was associated with reduced number of AHOs.
J Clin Oncol 35:1211-1222. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Testicular cancer (TC) is the most common cancer
among men age 18 to 39 years, with an age-
adjusted 5-year relative survival of 95%.1 This
remarkable success is explained in large part by the
introduction of platinum-based chemotherapy in
the 1970s.2 Today, the majority of patients with
metastatic TC receive standard cisplatin-based
chemotherapy, on the basis of international
guidelines3-5 related to prognostic groups.6 For two
decades, this standard chemotherapy has consisted
of three cycles of bleomycin, etoposide, and cis-
platin (BEPX3) or four cycles of etoposide and
cisplatin (EPX4) for good-risk TC or four cycles of
BEP (BEPX4) for intermediate- or poor-risk TC.7,8
Given the curative potential of these commonly
used regimens, it has become increasingly im-
portant to understand the occurrence of long-term
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adverse health outcomes (AHOs). As recently pointed out by
Oldenburg and Gietema,9 better characterization of AHOs may also
help guide TC treatment, especially in the controversial area of
whether patients with good-risk TC should receive EPX4 or BEPX3.
However, no series to date has quantiﬁed the type and prevalence of
long-term AHOs in large numbers of patients treated with EPX4,
BEPX3, or BEPX4. Although several European studies reported
toxicities in TC survivors (TCSs),10-14 many of these investigations
included older therapeutic regimens, and no study included more
than 10 patients treated with EPX4.
Characterization of long-term AHOs associated with modern
curative regimens is also important to develop risk-stratiﬁed,
evidence-based follow-up recommendations for TCSs, who now
comprise . 4% of all cancer survivors.15 Current follow-up
guidelines by national and international organizations3-5 for the
prevention and treatment of long-term toxicities are limited,
without broad consensus. The formulation of such guidelines,
including the development of interventions to prevent or mitigate
long-term effects, requires an assessment of AHOs, along with char-
acterization of potential risk factors.14,16,17 We aimed to provide new
information on the type and prevalence of AHOs in large numbers of
TCSs cured with either EP or BEP by initiating the Platinum Study,
a large multicenter cohort of US and Canadian TCSs.17
METHODS
Participants
The Platinum Study was approved by Institutional Review Boards at
all participating institutions. Each participant provided written informed
consent allowing access to medical records since cancer diagnosis.
Eligibility criteria included: histologic/serological diagnosis of germ
cell tumor (GCT), age , 55 years at diagnosis and . 18 years at en-
rollment, treatment with ﬁrst-line cisplatin-based chemotherapy for either
initial GCT or recurrence after active surveillance, no subsequent salvage
chemotherapy, no radiotherapy, no antecedent chemotherapy for another
primary cancer, and routine follow-up at the participating site. All par-
ticipants were disease-free at the time of clinical evaluation and are referred
to as TCSs.
Clinical Evaluation
TCSs underwent a brief physical examination and extensive audiometric
testing, with the latter results published separately.18 Body mass index (kg/m2)
was deﬁned as normal, overweight, obese, or morbidly obese (, 25, 25
to, 30, 30 to 39, and$ 40 kg/m2, respectively), with$ 30 kg/m2 considered
an AHO.19 Waist circumference . 102 cm deﬁned abdominal obesity.20
Patient-Reported Health Outcomes and Lifestyle Behaviors
TCSs completed a questionnaire regarding selected health outcomes
that were targeted largely to those associated with cisplatin-based che-
motherapy or with a TC diagnosis; in addition, lifestyle behaviors and
current prescription medications were queried. Each of the following
conditions was considered an AHO (deﬁnitions are listed in Appendix
Table A1, online only): tinnitus, hearing impairment, peripheral neu-
ropathy, problem with balance/vertigo/dizziness, renal disease, coronary
artery disease (CAD), heart failure, cerebrovascular disease, hypertension
and on prescription medication, Raynaud phenomenon, hypercholester-
olemia and on prescription medication, peripheral vascular disease,
thromboembolic disease, diabetes and on prescription medication, and
hypogonadismwith testosterone replacement. Obesity, use of psychotropic
prescription medications, erectile dysfunction, and benign thyroid disease
were each counted as an AHO. Chemotherapy-induced peripheral neu-
ropathy was assessed through the European Organization for Research and
Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20
scale23 and the Scale for Chemotherapy-Induced Long-Term Neurotox-
icity.21 Peripheral neuropathy was diagnosed if participants reported “quite
a bit” or “very much” to relevant questions.21,23 TCS also self-rated health
as excellent, very good, good, fair, or poor.
TCSs reported the average time per week engaged in various physical
activities during the past year.24 Total kilocalories per week were estimated
by summing metabolic equivalent (MET) –hours for each physical activity
and multiplying by the participant’s weight (kilograms). Kilocalories per
week were calculated for vigorous ($ 6 METs) and moderate (3 to , 6
METs) physical activities.25
Data Collection From Medical Records
Study staff were trained in person to abstract data according to
a standard protocol using forms adapted from prior studies.26-31 Data
included GCT diagnosis, and for each cytotoxic drug: name, dose, date(s)
of administration, number of cycles, and cumulative dose. All data were
entered into the eClinical system.32
Comparison Cohort
Matched controls for selected comparisons were chosen from the
National Health and Nutrition Examination Survey (NHANES) using two
consecutive data sets (2009 to 2012), following methods applied by the St
Jude’s Lifetime Cohort.33 Controls (restricted to men without cancer) were
matched 1:1 on race, age (within 5 years), educational level, and fasting
status at blood collection.
Statistical Analysis
Data were summarized with medians (ranges) for continuous var-
iables and proportions for categorical variables. To evaluate associations of
clinical, demographic, and behavioral risk factors with AHO number,
multinomial logistic regression, including all clinically relevant variables
known to affect health outcomes, estimated the adjusted (multivariable)
odds ratios (ORs), 95% CIs, and P values. For comparisons with NHANES
controls, multinomial or binary logistic regression estimated the relative
odds of TCSs having one of the following: elevated body mass index; waist
circumference$ 102 cm; self-reported hypertension; elevated fasting total
cholesterol ($ 240 mg/dL), LDL $ 160 mg/dL, or triglyceride
concentration $ 150 mg/dL; decreased fasting HDL (, 40 mg/dL);
smoking status (ever, current); alcohol consumption . 2 d/wk; and
self-reported health. Comparisons with lipid values were restricted to
participants who fasted for at least 8 hours before venipuncture (N = 131
TCSs, N = 131 controls). All tests were two-tailed (a = 0.05). The Mantel
1df x2 test for trend was used to determine the association between AHO
number and self-rating of health. Data were analyzed with SAS statistical
software program (SAS Institute Inc, Cary, NC).
RESULTS
Study Subjects
Of 1,024 eligible subjects, 952 (93.0%) consented to partic-
ipate. Reasons for nonparticipation included lack of interest
(n = 27), time commitment (n = 17), travel (n = 14), and mis-
cellaneous concerns (n = 14). Participants and nonparticipants
were similar in terms of age at TC diagnosis (P = .52), age at
assessment (P = .40), and race (P = .25). Of all patients, 950 were
seen in clinic as part of a scheduled follow-up visit and two were
seen because of concern regarding recurrence. No patients were
seen for treatment-related adverse effects.
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Table 1. Clinical and Sociodemographic Characteristics of 952 Survivors of Cisplatin-Treated Germ Cell Tumors by Treatment Regimen
Characteristic All Patients
Treatment Regimen
EPX4 BEPX3 BEPX4
Total 952a (100) 294 (100) 364 (100) 170 (100)
Clinical characteristic
Age at diagnosis, years
Median (range) 31 (15-53) 32 (17-53) 30 (15-50) 29 (16-49)
Age at clinical evaluation, years
Median (range) 37 (19-68) 39 (20-68) 37 (19-66) 36 (30-61)
, 20 5 (0.5) 0 5 (1.4) 0
20-29 196 (20.6) 51 (17.3) 81 (22.2) 36 (21.2)
30-39 357 (37.5) 105 (35.7) 137 (37.6) 72 (42.4)
40-49 252 (26.5) 72 (24.5) 99 (27.2) 49 (28.8)
$ 50b 142 (14.9) 66 (22.4) 42 (11.6) 13 (7.6)
Histologic type
Seminoma 253 (26.6) 106 (36.1) 92 (25.3) 30 (17.6)
Nonseminomac 699 (73.4) 188 (63.9) 272 (74.7) 140 (82.4)
Site
Testisd 842 (88.5) 276 (93.9) 338 (92.9) 140 (82.4)
Extragonadale 110 (11.5) 18 (6.1) 26 (7.1) 30 (17.6)
Cisplatin-based chemotherapyf
BEPg 557 (58.5) — 364 (100) 170 (100)
EPh 302 (31.7) 294 (100) — —
Otheri 93 (9.8) — — —
Cumulative dose of cisplatin, mg/m2
, 300 43 (4.5) 0 19 (5.2) 1 (0.6)
300 340 (35.7) 0 335 (92.0) 0
301-399 34 (3.6) 0 10 (2.7) 15 (8.8)
400 495 (52.0) 290 (98.6) 0 141 (82.9)
. 400 40 (4.2) 4 (1.4) 0 13 (7.6)
Cumulative dose of bleomycin, IU
0 368 (38.7) 294 (100) 0 0
. 0-180,000 57 (6.0) 0 10 (2.7) 17 (10.0)
181,000-270,000 385 (40.4) 0 353 (97.0) 26 (15.3)
271,000-360,000 136 (14.3) 0 1 (0.3) 126 (74.1)
. 360,000 6 (0.6) 0 0 1 (0.6)
Calendar year of chemotherapy completion
Before 2000j 95 (10.0) 23 (7.8) 33 (9.1) 19 (11.2)
2000-2009 368 (38.6) 123 (41.8) 126 (34.6) 70 (41.2)
2010-2015 489 (51.4) 148 (50.3) 205 (56.3) 81 (47.6)
Retroperitoneal lymph node dissection
Yes 455 (47.8) 161 (54.8) 122 (33.5) 113 (66.5)
Nok 497 (52.2) 133 (45.2) 242 (66.5) 57 (33.5)
Time from chemotherapy completion to clinical evaluation,
years
Median (range) 4.3 (1.0-29.9) 4.3 (1-23.9) 3.8 (1-25.3) 5.1 (1-23.7)
, 2 225 (23.6) 70 (23.8) 99 (27.2) 30 (17.7)
2-5 355 (37.3) 106 (36.1) 139 (38.2) 65 (38.2)
6-9 168 (17.7) 52 (17.7) 61 (16.7) 33 (19.4)
$ 10 204 (21.4) 66 (22.4) 65 (17.9) 42 (24.7)
Sociodemographic characteristic
Race
White 817 (85.8) 246 (83.7) 330 (90.7) 141 (82.9)
Nonwhitel 135 (14.2) 48 (16.3) 34 (9.3) 29 (16.1)
Marital status
Not marriedm 366 (38.5) 109 (37.1) 130 (35.7) 73 (42.9)
Married/living as married 586 (61.5) 185 (62.9) 234 (64.3) 97 (57.1)
Education
High school or less 109 (11.4) 17 (5.8) 42 (11.5) 32 (18.8)
Some college/college graduate 627 (65.9) 201 (68.4) 243 (66.8) 108 (63.5)
Postgraduate level 203 (21.3) 75 (25.5) 74 (20.3) 26 (15.3)
Other or unknown 13 (1.4) 1 (0.3) 5 (1.4) 4 (2.4)
(continued on following page)
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Population Characteristics
Chemotherapy consisted largely of BEPX3 (38.2%), EPX4
(30.9%), and BEPX4 (17.9%; Table 1). Median age at clinical
evaluation was 37 years (range, 19 to 68 years), and median time
since chemotherapy completion was 4.3 years (range, 1.0 to 29.9
years). Most (85.8%) TCSs were white,35 married or cohabitating
(61.5%), and had at least a college education (64.0%). Clinical and
sociodemographic characteristics were comparable for EPX4 and
BEPX3 (P . .05), except for race and educational status (each
P , .01).
More than 70% of TCSs were overweight (42.4%) or obese
(30.9%; Table 2). Only 8.3% of participants currently smoked;
11.4% consumed two or more alcoholic drinks daily, and 69.0%
engaged in weekly vigorous-intensity physical activity. Physical
examination ﬁndings and health behaviors were similar for EPX4
and BEPX3 (P . .05), except for smoking status (P , .01).
AHOs
Overall, 79.6% TCSs reported at least one AHO, and 20.1%,
15.0%, 10.1%, and 12.5% reported two, three, four, or ﬁve or
more AHOs, respectively (Table 3). Median number of AHOs
after EPX4 or BEPX3 was two, with 34.3% and 35.1% of TCSs
reporting three or more AHOs, respectively. The type and
prevalence of individual AHOs after EPX4 and BEPX3 were
similar (P. .05), except Raynaud phenomenon (11.6% v 21.4%;
P , .01), peripheral neuropathy (29.2% v 21.4%; P = .02), and
obesity (25.5% v 33.0%; P = .04). Among all TCSs, the most
common AHOs were tinnitus (37.1%), self-reported hearing
impairment (31.5%), obesity (30.9%), and peripheral neurop-
athy (27.0%). Both peripheral neuropathy and tinnitus and/or
hearing impairment were reported by one in six (16.4%) TCSs.
Current prescription medication use for hypertension, hyper-
cholesterolemia, and diabetes was noted by 11.6%, 10.5%, and
3.1% of TCSs, respectively. After BEPX4, the type and prevalence
of AHOs were similar to EPX4 and BEPX3, with the exception of
erectile dysfunction (20.0%).
Number of AHOs was inversely associated with self-rating of
health (Fig 1), with the latter declining as AHO numbers increased
(P , .001). Among 194 TCSs with no AHOs, 80.4%, 18.6%, and
1.0% self-reported health as excellent/very good, good, or fair/poor.
In contrast, among 119 TCSs with ﬁve or more AHOs, the com-
parable percentages were 26.9%, 56.3%, and 16.8%, respectively.
Increasing age at clinical evaluation was associated with sig-
niﬁcantly increased risks of one to two, three to four, or ﬁve or
Table 1. Clinical and Sociodemographic Characteristics of 952 Survivors of Cisplatin-Treated Germ Cell Tumors by Treatment Regimen (continued)
Characteristic All Patients
Treatment Regimen
EPX4 BEPX3 BEPX4
Employment status
Not employedn 103 (10.8) 32 (10.9) 33 (9.1) 20 (11.8)
Employed 849 (89.2) 262 (89.1) 331 (90.9) 150 (88.2)
NOTE. Data presented as No. (%) unless otherwise noted. Of 1,024 eligible subjects, 952 (93%) consented to participate. Reasons for nonparticipation included lack of
interest (n = 27), time commitment (n = 17), travel (n = 14), and other concerns: inconvenience (n = 4), concernwith study procedures (n = 3), conﬁdentiality issues (n = 2),
health issues (n = 2), lack of insurance (n = 1), and unspeciﬁed reasons (n = 2). Of the 952 patients, 950 were seen in clinic as part of a scheduled follow-up visit and two
were seen because of concern regarding recurrence. Clinical and sociodemographic characteristics were comparable for EPX4 and BEPX3 (P. .05), except for race and
educational level (P , .01 each).
Abbreviations: BEPX3, three cycles of bleomycin, etoposide, cisplatin; BEPX4, four cycles of bleomycin, etoposide, cisplatin; EPX4, four cycles of etoposide, cisplatin;
PVB, cisplatin, vinblastine, bleomycin; RPLND, retroperitoneal lymph node dissection; TCS, testicular cancer survivor; VeIP, vinblastine, ifosfamide, cisplatin; VIP,
etoposide, ifosfamide, cisplatin.
aOf 952 patients in the study, most received EPX4 (n = 294), BEPX3 (n = 364), and BEPX4 (n = 170). The remainder received BEP other than three or four cycles (n = 23),
EP other than four cycles (n = 8), and other regimens (n = 93). The other regimens consisted of other cisplatin-based regimens (n = 70), VIP (n = 22), and VeIP (n = 1).
bFourteen participants were between 60 to 69 years of age at clinical evaluation.
cIncludes eight participants with not-otherwise-speciﬁed germ cell tumor, with one participant with unknown histology.
dFive participants had bilateral testicular cancer.
eFifty-nine, 36, and 14 participants had extragonadal germ cell tumors of the mediastinum, retroperitoneum, and other sites, respectively. This category also includes
one participant with primary site not stated.
fEighteen (1.9%), 374 (39.3%), 535 (56.2%), and 25 (2.6%) participants received two or fewer, three, four, and ﬁve or more cycles of cisplatin-based chemotherapy,
respectively.
gIncludes 130 (23.3%) participants withmodiﬁcation of dosing and schedules of BEP. The remaining 427 participants (76.7%) received the standard dosing and standard
BEP schedule: each chemotherapy cycle consists of bleomycin, 30,000 IU days 1, 8, and 15; etoposide 100 mg/m2 days 1 through 5; and cisplatin 20 mg/m2 days 1
through 5. In addition, 364 (65.4%) and 170 (30.5%) participants received three and four cycles of BEP, respectively. The median cumulative cisplatin doses for the BEP
group were 300 mg/m2 (range, 198 to 653 mg/m2).
hIncludes 112 (37.1%) participants with modiﬁcation of dosing and schedules of EP. The remaining 190 participants (62.9%) received the standard dosing and standard
EP schedule: each chemotherapy cycle consists of etoposide 100 mg/m2 days 1 through 5 and cisplatin 20 mg/m2 days 1 through 5. The median cumulative cisplatin
doses for the EP group were 400 mg/m2 (range, 200 to 600 mg/m2).
iIncludes 70 participants with other cisplatin-based regimens, 22 participants with VIP and one participant with VeIP, but none with PVB. Each standard VIP che-
motherapy cycle consists of etoposide 75 mg/m2 days 1 through 5, cisplatin 100 mg/m2 days 1 through 5, and ifosfamide 1,200 mg/m2 days 1 through 5.
jTwo participants completed chemotherapy before 1990. Among the 95 participants who completed chemotherapy before 2000, none reported that the indication for
the clinic visit was concern about late effects; in 94 it was for routine follow-up, and one patient indicated “other reason, not speciﬁed.”
kIncludes three participants with retroperitoneal lymph node dissection status not stated. The lower number of TCSs having retroperitoneal lymph node dissection in
BEPX3 (33.5%) compared with EPX4 (47.8%) likely reﬂects the different clinical practices for management of advanced testicular cancer at our study institutions,
including types of chemotherapy used (BEPX3 v EPX4), and if RPLNDwas performed among patients with disseminated testicular cancer having a radiographic complete
response after chemotherapy. Retrograde ejaculation is the most common long-term complication after nerve-sparing postchemotherapy RPLND and can affect 11% to
29% of TCSs.34
lThe nonwhite population consisted of 11 (1.2%) black/African American, 44 (4.6%) Asian, one (0.1%) American Indian, 12 (1.3%) who identiﬁed more than one race,
61 (6.4%) other race, and six (0.6%) whose race was not stated.
mIncludes 12 participants with marital status not stated.
nIncludes 15 participants with employment status not stated.
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more AHOs, compared with no AHOs (OR, 1.22, 1.50, and 1.87,
respectively), whereas vigorous physical activity was associated
with signiﬁcantly decreased AHOs (OR, 0.62, 0.51, and 0.41, re-
spectively; Table 4). Cumulative bleomycin dose was signiﬁcantly
associated with ﬁve or more AHOs (OR, 1.44 [95% CI, 1.20 to
1.71] per 90,000 IU), with nonsigniﬁcant risks of the same
magnitude (OR, 1.40 [95% CI, 0.95 to 2.05] per 100 mg/m2) for
cumulative cisplatin dose. When AHOs were limited to those
previously linked to cisplatin (peripheral neuropathy, hearing loss,
tinnitus), ORs (per 100 mg/m2) for one (n = 288), two (n = 185),
and three (n = 84) AHOs compared with no AHOs were 1.14 (95%
CI, 0.87 to 1.49; P = .34), 1.48 (95% CI, 1.11 to 1.97; P = .01), and
1.46 (95% CI, 1.002 to 2.13; P = .05), respectively (footnote,
Table 4). For Raynaud syndrome, the OR (per 100 mg/m2 of
cisplatin) was 1.0 (95% CI, 0.77 to 1.29), and for bleomycin, the
OR (per 90,000 IU) was 1.31 (95% CI, 1.16 to 1.47).
Statistically signiﬁcant risk factors for three to four AHOs also
included noncollege graduate (OR, 1.88), nonmarried status (OR,
1.85), and current (OR, 3.05) or former smoking (OR, 1.61). These
characteristics were also associated with signiﬁcantly increased
risks of ﬁve or more AHOs (OR, 2.57, 1.89, 3.73, and 1.76,
respectively).
Compared with matched NHANES controls, TCS had sig-
niﬁcantly higher risks of elevated concentrations of fasting total
Table 2. Physical Examination Findings and Health Behaviors for 952 Survivors of Cisplatin-Treated Germ-Cell Tumors by Treatment Regimen
Characteristic All Patients*
Treatment Regimen
EPX4 BEPX3 BEPX4
Total 952 (100) 294 (100) 364 (100) 170 (100)
Physical examination results
Body mass index, kg/m2
Median (range) 28 (18-67) 27 (18-49) 28 (18-67) 28 (18-66)
, 25 (normal) 241 (25.3) 77 (26.2) 91 (25.0) 38 (22.4)
25-29 (overweight) 404 (42.4) 137 (46.6) 150 (41.2) 71 (41.8)
30-39 (obese) 259 (27.2) 66 (22.4) 103 (28.3) 55 (32.4)
$ 40 (morbidly obese) 35 (3.7) 9 (3.1) 17 (4.7) 3 (1.7)
Not available 13 (1.4) 5 (1.7) 3 (0.8) 3 (1.7)
Waist circumference, cm
Median (range) 94 (57-190) 93 (62-145) 94 (57-180) 95 (73-190)
, 102 673 (70.7) 218 (74.1) 256 (70.3) 109 (64.1)
$ 102 264 (27.7) 74 (25.2) 101 (27.7) 58 (34.1)
Not available 15 (1.6) 2 (0.7) 7 (1.9) 3 (1.8)
Weight gain since chemotherapy, pounds†
None 9 (1.0) 7 (2.4) 1 (0.3) 0
, 10 405 (42.5) 147 (50.0) 160 (44.0) 55 (32.4)
11-20 102 (10.7) 30 (10.2) 31 (8.5) 24 (14.1)
. 20 41 (4.3) 5 (1.7) 9 (2.5) 14 (8.2)
Lost weight 246 (25.8) 85 (28.9) 94 (25.8) 38 (22.4)
Not available 149 (15.7) 20 (6.8) 69 (18.9) 39 (22.9)
Health behavior
Smoking status
Never smoker 552 (58.0) 155 (52.7) 233 (64.0) 91 (53.5)
Former smoker 321 (33.7) 124 (42.2) 102 (28.0) 58 (34.1)
Current smoker 79 (8.3) 15 (5.1) 29 (8.0) 21 (12.4)
Average No. of alcoholic drinks in past year
Rarely or never 182 (19.1) 46 (15.6) 72 (19.8) 43 (25.3)
# 4 per week 436 (45.8) 153 (52.0) 153 (42.0) 66 (38.8)
5 per week to 1 per day 221 (23.2) 65 (22.1) 96 (26.4) 37 (21.8)
$ 2 per day 108 (11.4) 28 (9.5) 42 (11.5) 22 (12.9)
Not stated 5 (0.5) 2 (0.7) 1 (0.3) 2 (1.2)
Moderate-intensity physical activity (3 to , 6 METs)‡§
Any moderate-intensity activity 912 (95.8) 285 (97.0) 351 (96.4) 162 (95.3)
Vigorous-intensity physical activity ($ 6 METs)‡§
Any vigorous-intensity activity 657 (69.0) 207 (70.4) 261 (71.7) 108 (63.5)
NOTE. Data presented as No. (%) unless otherwise noted.
Abbreviations: BEPX3, three cycles of bleomycin, etoposide, cisplatin; BEPX4, four cycles of bleomycin, etoposide, cisplatin; EPX4, four cycles of etoposide, cisplatin;
METs, metabolic equivalents.
*Please refer to Table 1 footnotes for a description of chemotherapy regimens. Physical examination ﬁndings and health behaviors were similar for EPX4 and BEPX3
(P . .05), except for smoking status (P , .01).
†Objective weight gain since chemotherapy was calculated by subtracting the weight recorded at the time of chemotherapy from the weight recorded at the time of
clinical evaluation.
‡Among all participants, the median total kilocalories expended per week (interquartile range) was 991 (207 to 2,342). Each physical activity was assigned a MET value
(1 MET = 1 kcal/kg/h, or the energy cost of sitting quietly) fromwhich MET-hours per week were calculated. Total kilocalories per week were calculated by summing the
product of the time per week engaged in speciﬁc physical activities and MET value equivalents for this activity and then multiplying this value by the subject’s weight (in
kilograms).25,36
§Themoderate-intensity and vigorous-intensity physical activity groups are notmutually exclusive. Nine different activitieswere surveyed, some ofwhich aremoderate-
intensity activities and some ofwhich are vigorous-intensity activities. If a participant reported that he spent 1 hour walking per week (ie, amoderate-intensity activity) and
30 minutes running per week (ie, a vigorous-intensity activity), he was included as a yes for both any moderate and any vigorous activity.25,36
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Table 3. Numbers and Types of Self-Reported AHOs Among 952 Cisplatin-Treated Germ Cell Tumor Survivors
AHO
Total Patients
(N = 952)
Treatment Regimen
EPX4 (n = 294) BEPX3 (n = 364) BEPX4 (n = 170)
Total No. of AHO
Median (range) 2 (0-11) 2 (0-9) 2 (0-11) 2 (0-10)
0 194 (20.4) 64 (21.8) 83 (22.8) 25 (14.7)
1 209 (21.9) 68 (23.1) 71 (19.5) 42 (24.7)
2 191 (20.1) 61 (20.8) 82 (22.5) 27 (15.9)
3 143 (15.0) 48 (16.3) 48 (13.2) 25 (14.7)
4 96 (10.1) 28 (9.5) 38 (10.4) 18 (10.6)
$ 5 119 (12.5) 25 (8.5) 42 (11.5) 33 (19.4)
No. of AHOs by time since chemotherapy completion, years
, 2 2 (0-11) 2 (0-7) 1 (0-11) 2 (0-6)
2-5 2 (0-10) 2 (0-8) 2 (0-7) 2 (0-8)
6-9 2 (0-9) 1 (0-7) 2 (0-7) 1 (0-6)
$ 10 3 (0-10) 3 (0-9) 3 (0-7) 2 (0-10)
Number of AHOs by age at clinical evaluation, years
# 29 1 (0-7) 1 (0-6) 1 (0-6) 2 (0-6)
30-39 2 (0-10) 1 (0-7) 2 (0-6) 2 (0-10)
40-49 2 (0-11) 2 (0-7) 2 (0-11) 3 (0-8)
$ 50 3 (0-10) 3 (0-9) 3 (0-7) 5 (0-10)
Type of AHOa
Tinnitus
Yes 353 (37.1) 104 (35.4) 130 (35.7) 65 (38.2)
Nob 599 (62.9) 190 (64.6) 234 (64.3) 105 (61.8)
Hearing impairmentc
Yes 300 (31.5) 95 (32.3) 109 (30.0) 56 (33.0)
No 652 (68.5) 199 (67.7) 255 (70.0) 114 (67.0)
Peripheral neuropathyd
Yes 257 (27.0) 86 (29.2) 78 (21.4) 54 (31.8)
No 695 (73.0) 208 (70.8) 286 (78.6) 116 (68.2)
Peripheral neuropathy plus tinnitus and/or hearing issue
Yes 156 (16.4) 49 (16.7) 48 (13.2) 31 (18.2)
No 796 (83.6) 245 (83.3) 316 (86.8) 139 (81.8)
Hypertension and on prescription medication
Yes 110 (11.6) 35 (11.9) 45 (12.4) 15 (8.8)
Noe 842 (88.4) 259 (88.1) 319 (87.6) 155 (91.2)
Hypercholesterolemia and on prescription medication
Yes 100 (10.5) 32 (10.9) 31 (8.5) 20 (11.8)
Nof 852 (89.5) 262 (89.1) 333 (91.5) 150 (88.2)
Cardiovascular diseaseg
Yes 14 (1.5) 4 (1.4) 4 (1.1) 2 (1.2)
Noh 938 (98.5) 290 (98.6) 360 (98.9) 168 (98.8)
Raynaud phenomenon
Yes 178 (18.7) 34 (11.6) 78 (21.4) 49 (28.8)
Noi 774 (81.3) 260 (88.4) 286 (78.6) 121 (71.2)
Peripheral vascular disease
Yes 29 (3.0) 5 (1.7) 8 (2.2) 10 (5.9)
Noj 923 (97.0) 289 (98.3) 356 (97.8) 160 (94.1)
Thromboembolic diseasek
Yes 5 (0.5) 0 0 4 (2.4)
No 947 (99.5) 294 (100) 364 (100) 166 (97.6)
Renal disease
Yes 25 (2.6) 7 (2.4) 6 (1.6) 7 (4.1)
Nol 927 (97.4) 287 (97.6) 358 (98.4) 163 (95.9)
Diabetes and on prescription medicationm
Yes 30 (3.1) 9 (3.1) 10 (2.7) 3 (1.8)
No 922 (96.9) 285 (96.9) 354 (97.3) 167 (98.2)
Benign thyroid disease
Yes 23 (2.4) 6 (2.0) 9 (2.5) 5 (2.9)
Non 929 (97.6) 288 (98.0) 355 (97.5) 165 (97.1)
Problems with balance/vertigo/dizzinesso
Yes 89 (9.3) 26 (8.8) 37 (10.2) 16 (9.4)
No 863 (90.7) 268 (91.2) 327 (89.8) 154 (90.6)
Hypogonadism with testosterone therapyp
Yes 93 (9.9) 25 (8.6) 37 (10.3) 16 (9.5)
No 851 (90.1) 267 (91.4) 323 (89.7) 152 (90.5)
(continued on following page)
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cholesterol (OR, 4.76) and LDL cholesterol (OR = 2.42) but lower
risks of increased fasting HDL cholesterol (OR, 0.38; P = .001;
Table 5). TCSs had signiﬁcantly higher self-reported health and
were less likely to be current (OR, 0.22; P , .001) or ever smokers
(OR, 0.64; P , .001).
DISCUSSION
The Platinum Study represents the largest cohort to date of TCSs
treated with EPX4, BEPX3, and BEPX4 with an assessment of the
prevalence and type of AHOs. A new ﬁnding includes that more
than one third of TCSs at a median age of 37 years reported three or
more AHOs, with similar prevalence and type after EPX4 and
BEPX3, except for peripheral neuropathy, Raynaud phenomenon,
and obesity. Factors consistently associated with increased num-
bers of AHOs included age at clinical evaluation, current smoking,
lower educational attainment, and nonmarried status. Weekly
vigorous physical activity was noteworthy for its uniformly inverse
association with AHOs. Self-reported health was excellent/very
good in 59.9% of TCSs, but decreased as AHOs increased
(P , .001). These and other new ﬁndings are discussed below.
AHOs: Quantification and Type by Treatment Regimen
Prior studies of BEP included a median of 126 patients (range,
25 to 287), and EPX4 could not be separately evaluated because
fewer than 10 patients received the latter regimen.10,11,37-39 Of four
small US-based investigations,40-43 a limited number of AHOs was
addressed in one series (143 patients)41 but also included treat-
ments with carboplatin-based and other non–cisplatin-based
regimens and excluded established cisplatin complications
(eg, neuropathy).
Both ototoxicity and cisplatin-induced peripheral neuropathy
were reported by one in six TCSs, a combination of symptoms that
to our knowledge have not yet been jointly evaluated. This ﬁnding
is particularly noteworthy, because preliminary genetic analyses
Table 3. Numbers and Types of Self-Reported AHOs Among 952 Cisplatin-Treated Germ Cell Tumor Survivors (continued)
AHO
Total Patients
(N = 952)
Treatment Regimen
EPX4 (n = 294) BEPX3 (n = 364) BEPX4 (n = 170)
Erectile dysfunction
Yes 115 (12.1) 28 (9.5) 39 (10.7) 34 (20.0)
Noq 837 (87.9) 266 (90.5) 325 (89.3) 136 (80.0)
Psychotropic prescription medication for anxiety and/or
depressionr
Yes 99 (10.4) 34 (11.6) 27 (7.4) 20 (11.8)
No 853 (89.6) 260 (88.4) 337 (92.6) 150 (88.2)
NOTE. Data presented as No. (%) or median (range). Refer to Appendix Table A1 for deﬁnitions of each AHO.
Abbreviations: AHO, adverse health outcome; BEPX3, three cycles of bleomycin, etoposide, cisplatin; BEPX4, four cycles of bleomycin, etoposide, cisplatin; CAD,
coronary artery disease; DVT, deep vein thrombosis; EORTC-CIPN20, European Organization for Research and Treatment of Cancer Chemotherapy-Induced Peripheral
Neuropathy 20 Scale; EPX4, four cycles of etoposide, cisplatin; SCIN, Scale for Chemotherapy-Induced Long-Term Neurotoxicity; TCS, testicular cancer survivor.
aP values derived from the x2 test comparing the proportions of AHOs reported by TCSs in the EPX4 and BEPX3 treatment groups. Except for Raynaud phenomenon
(P , .01) and peripheral neuropathy (P = .02), the P values for all other AHOs were . .05.
bCategory includes three participants for whom this outcome was not stated.
cAmong all 952 participants, 270 (28.4%) reported problems hearing words, sounds, or language in crowds, 13 (1.4%) required hearing aid, and two (0.2%) had
complete deafness (questions derived from the hearing handicap inventory by Ventry and Weinstein22); 109 (11.4%) had “quite a bit” or “very much” difﬁculty hearing,
and 75 (7.9%) had “quite a bit” or “very much” reduced hearing (EORTC-CIPN20 and SCIN).21,23 Category includes 48 participants for whom this outcome was not
stated.
dAmong all 952 participants, the number of patients reporting “quite a bit” or “very much” to the following questions are as follows: 123 (12.9%) tingling ﬁngers or
hands, 167 (17.5%) tingling toes or feet, 121 (12.7%) numbness in ﬁngers or hands, 161 (16.9%) numbness in toes or feet, 34 (3.6%) shooting/burning pain in ﬁngers or
hands, 70 (7.4%) shooting/burning pain in toes or feet (EORTC-CIPN20)23; 134 (14.1%) pain and tingling in toes or feet, and 86 (9.0%) pain and tingling in hands or ﬁngers
(SCIN).21 Category includes 16 participants for whom this outcome was not stated.
eCategory includes 11 participants for whom this outcome was not stated.
fCategory includes three participants for whom this outcome was not stated.
gIncludes CAD, heart failure, and cerebrovascular disease (categories notmutually exclusive and each categorywas counted as one AHO). Among all participants, seven
(0.7%) reported coronary artery disease (three occurrences for coronary artery disease, ﬁve occurrences of angioplasty or stent, and ﬁve occurrences of heart attack or
myocardial infarction), one patient reported heart failure, and 10 (1.0%) reported cerebrovascular disease (six occurrences of transient ischemic attacks, four occurrences
of stroke, and one occurrence of carotid artery surgery).
hCategory includes 21 participants for whom this outcome was not stated.
iCategory includes 12 participants for whom this outcome was not stated.
jCategory includes 19 participants for whom this outcome was not stated.
kDVT and pulmonary embolism developed simultaneously in three participants and was counted as one thromboembolic event for each. The remaining two participants
reported DVT only. Category includes 19 participants for whom this outcome was not stated.
lCategory includes 26 participants for whom this outcome was not stated.
mAmong all participants, 13 (1.4%) and 22 (2.3%) reported use of insulin and oral antiglycemic agents, respectively (categories not mutually exclusive). Category
includes 15 participants for whom this outcome was not stated.
nCategory includes 19 participants for whom this outcome was not stated.
oOf the 89 patients, 47 reported persistent dizziness or vertigo and 63 reported symptoms of dizziness when standing up (categories not mutually exclusive). Category
includes 40 participants for whom this outcome was not stated.
pEight participants who underwent bilateral orchiectomy were excluded from this category.
qCategory includes seven participants for whom this outcome was not stated.
rParticipants could report more than one psychotropic medication. Psychotropic medications used by the 99 participants include aripiprazole (n = 2), alprazolam (n = 5),
amphetamine-dextroamphetamine (n = 9), bupropion (n = 10), buspirone (n = 1), citalopram (n = 6), clonazepam (n = 8), desvenlafaxine (n = 1), diazepam (n = 1),
duloxetine (n = 7), escitalopram (n = 16), ﬂuvoxamine (n = 1), ﬂuoxetine (n = 4), hydroxyzine (n = 1), lisdexamfetamine (n = 4), lorazepam (n = 6), methylphenidate (n = 5),
nortriptyline (n = 2), olanzapine (n = 2), paroxetine (n = 7), trazodone (n = 5), sertraline (n = 11), and venlafaxine (n = 7).
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among our patients show that peripheral neuropathy–associated
genes demonstrate a striking enrichment for signiﬁcant gene-level
associations with ototoxicity (P , 2.2 3 10216).44 Understanding
the extent to which various cisplatin-related adverse effects may
share underlying genetic architecture provides an inroad into
delineating the underlying pathophysiology of symptom constel-
lations and the eventual development of preventive strategies.45
The highly signiﬁcant association between increasing age at
clinical evaluation and number of AHOs reﬂects in part comor-
bidities acquired with advancing age, apart from cisplatin-related
toxicities (Appendix Table A2, online only). Although no in-
dependent effect of time since chemotherapy was observed, this
likely reﬂects the relatively short follow-up duration and com-
mensurate weighting of results by acute-onset toxicities. Among
survivors of childhood cancer with substantially longer follow-
up,46 the number of AHOs indeed increases with time. In addition,
an important question not only for TCS but also for other patients
receiving cisplatin-based chemotherapy with long-term survival is
the extent to which the severity of selected acute-onset toxicities,
such as hearing loss, may be accelerated during the aging process.18
The signiﬁcant association between cumulative cisplatin dose
and the number of cisplatin-related AHOs extends existing evi-
dence that cisplatin contributes to the development of peripheral
neuropathy38,39 and ototoxicity,18,37,38 with dose-dependent re-
lationships noted previously for each individually.18,37,38 However,
for other AHOs, such as hypogonadism, orchiectomy likely partly
contributes, although evidence suggests that this outcome may be
accentuated in patients administered cisplatin-based chemother-
apy.47 Raynaud phenomenon is a known toxicity of bleomycin39
and may be associated with cisplatin.38 Although we found no
association with cumulative cisplatin dose and Raynaud phe-
nomenon, risk was signiﬁcantly elevated by 1.3-fold per 90,000-IU
increase in bleomycin dose, a ﬁnding consistent in part with
Glendenning et al,39 who evaluated risk in 180,000-IU increments
(OR, 2.9 per 180,000-IU increase; P , .001).
AHOs and Self-Reported Health
The extent to which increasing numbers of AHOs signiﬁcantly
and negatively affect self-reported health is noteworthy and un-
derscores the importance of patient-reported outcomes in survi-
vorship research. Norwegian TCSs had lowered Short Form-36
Physical Component summary scores48 and increased risks of anxiety
disorders, which were associated with peripheral neuropathy, com-
pared with age-adjusted normative data.49 Dahl et al14 reported that
neurotoxic adverse effects, anxiety/depression, and musculoskeletal
issues were associated with poor quality of life. Fleer et al50 found that
chronic disease was also a quality-of-life correlate, although an as-
sociation with number of conditions was not evaluated.
Cardiovascular Disease
Two European investigations10,11 evaluated cardiovascular
disease incidence and risk factors in at least 300 cisplatin-treated
TCSs (Appendix Table A3, online only). Among 390 TCSs treated
with BEP (n = 168), carboplatin-based regimens (n = 138), or
cisplatin, vinblastine, bleomycin (n = 19), a 6.7% incidence of
cardiovascular events was reported (median follow-up, 9.7
years),11 although results were not stratiﬁed by treatment. Haugnes
et al10 reported a CAD prevalence of 6.2% among 364 TCSs re-
ceiving BEP (n = 160; median follow-up, 19 years). The sub-
stantially lower CAD prevalence here likely reﬂects the shorter
follow-up, younger attained age, and differences in underlying risk
factors (eg, diet, activity) between US and European populations.51
Compared with NHANES controls, TCSs were 2.4- to 4.8-fold
more likely to demonstrate signiﬁcantly elevated fasting LDL and
total cholesterol. Use of lipid-lowering medications (10.5%) was
only slightly lower than in TCSs (14.0%) evaluated by Haugnes
et al10 (median age, 49 years). Although antihypertensive medi-
cation use in the Norwegian study was 26.0%,10 use in our patients
(11.6%) is comparable to the British cohort (13.3%; median
follow-up age, 41 years).11
AHOs and Health-Related Behaviors and
Sociodemographic Factors
To our knowledge, the association of physical activity on the
subsequent development of AHOs in TCSs has not been assessed in
US40-42 or European10-13 studies. Two US studies42,43 reported that
19% to 25% of TCSs continued to smoke after diagnosis, but
associations with AHOs were not evaluated. The low prevalence of
smoking here may reﬂect in part TCS management at large cancer
centers, many of which have smoking cessation programs.
TCSs with lower educational levels and those who were un-
married experienced greater numbers of AHOs, associations that to
our knowledge have not been previously examined in other US40-43
and European10-13 TCS studies. In the Childhood Cancer Survivor
Study,52 lower educational attainment was signiﬁcantly associated
(OR, 2.0) with at least one adverse health status domain. In contrast,
for adult-onset cancer survivors, to our knowledge there are no data
addressing the effect of sociodemographic parameters on AHOs,
although these characteristics have been evaluated in terms of in-
ﬂuence on cancer diagnosis, treatment, and survival. For example,
lower socioeconomic level and single status are associated with
cancer diagnoses at more advanced stages, receipt of less-aggressive
treatment, and increased cancer-speciﬁc and all-cause mortality.53-55
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Fig 1. Proportion of testicular cancer survivors (TCSs) with excellent, very good,
good, fair, and poor self-reported health by number of adverse health outcomes
(AHOs). P value for association of number of AHOs with self-reported health was
, .01 (Mantel 1df x2 test of trend). Self-reported health was not indicated by one
participant with one to two AHOs and one participant with three to four AHOs.
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Strengths and Limitations
A major strength of our study is that our estimate of the type
and prevalence of AHOs is based on the largest number of TCSs to
date treated with EPX4, BEPX3, and BEPX4, with results stratiﬁed
by regimen. Other strengths include the high participation rate
(93%), physical examinations, medical chart abstraction, assess-
ment of AHOs and health behaviors, and estimation of risk
without the confounding effect of radiotherapy. Although our
investigation included many AHOs, it was largely focused on
cisplatin-related toxicities and thus did not include psychosocial/
mental health outcomes or pulmonary toxicity. Because bleomycin
is avoided in patients at high risk for lung toxicity, we do not expect
the low prevalence of clinically signiﬁcant pulmonary toxicity to
materially affect our overall conclusions.56 Nonetheless, our results
should be considered aminimal estimate of AHOnumber, without an
assessment of severity and with a relatively short median follow-up
time. Furthermore, some toxicities may be underestimated; for ex-
ample, in our prior report,18 self-reported hearing loss was 31.5%
compared with 80% hearing deﬁcits detected by objective audio-
metric evaluation. As in previous studies of TCSs14,40,42 and adult
survivors of childhood cancer,57,58 AHOs were largely self-reported,
without baseline data before treatment. Any cross-sectional design has
potential inherent limitations and does not allow us to infer causation
of evaluated risk factors to AHOs and determine the exact prevalence,
although prospective data collection is planned. Moreover, our AHO
estimates represent the long-term effects of EPX4, BEPX3, and BEPX4
as administered at major cancer centers; thus, our results may not be
generalizable to community-based settings.
In conclusion, at a median follow-up of 4.3 years, the
prevalence and type of AHOs among TCSs receiving EPX4, BEPX3,
or BEPX4 appear largely similar, although a strong inﬂuence of
increasing age is apparent. Because alterations in the successful TC
regimens are unlikely, our results underscore the importance of
continued follow-up of TCSs to determine the extent to which
AHOs might increase as the cohort matures.9 Similarly, ongoing
genetic research to broaden our understanding of the biologic basis
and causal pathways of cisplatin-associated AHOs44,45,59 is needed
to form the foundation for the development of preventive and
interventional strategies. Although increasing numbers of AHOs
were associated with a signiﬁcant decline in self-reported health,
Table 4. Multinomial Logistic Regression Analyses of AHOs in 915 Survivors of Cisplatin-Treated Germ Cell Tumors
Characteristic
No. of AHOs
1-2 v 0 3-4 v 0 $ 5 v 0
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Clinical
Age at clinical evaluation, per 5 years 1.22 (1.07 to 1.39) .003 1.50 (1.30 to 1.73) < .001 1.87 (1.56 to 2.23) < .001
Cumulative dose of cisplatin,* per 100 mg/m2 1.13 (0.83 to 1.54) .437 1.18 (0.84 to 1.67) .342 1.40 (0.95 to 2.05) .091
Cumulative dose of bleomycin, per 90,000 IU 1.05 (0.93 to 1.20) .430 1.07 (0.93 to 1.24) .370 1.44 (1.20 to 1.71) < .001
Time since chemotherapy completion, per year 0.98 (0.94 to 1.02) .308 0.98 (0.93 to 1.02) .286 0.97 (0.92 to 1.02) .269
Sociodemographic
Race
Nonwhite 0.85 (0.52 to 1.42) .540 0.61 (0.33 to 1.13) .117 0.42 (0.17 to 1.04) .061
White — Ref — Ref — Ref
Education
Not college graduate 1.35 (0.88 to 2.06) .165 1.88 (1.18 to 2.99) .008 2.57 (1.46 to 4.53) .001
College or post graduate — Ref — Ref — Ref
Marital status
Not married 1.48 (0.97 to 2.25) .067 1.85 (1.15 to 2.97) .011 1.89 (1.04 to 3.44) .036
Married/living as married — Ref — Ref — Ref
Health behavior
Smoking status
Current smoker 2.46 (0.98 to 6.20) .056 3.05 (1.13 to 8.22) .028 3.73 (1.21 to 11.46) .022
Former smoker 1.05 (0.71 to 1.56) .806 1.61 (1.04 to 2.50) .034 1.76 (1.01 to 3.06) .045
Never smoker — Ref — Ref — Ref
Average No. of alcoholic drinks in past year
# 4 per week 0.78 (0.46 to 1.32) .361 0.62 (0.35 to 1.10) .102 0.73 (0.36 to 1.46) .370
5 per week to 1 per day 0.93 (0.51 to 1.68) .804 0.70 (0.36 to 1.35) .283 0.52 (0.22 to 1.23) .137
$ 2 per day 1.41 (0.64 to 3.07) .393 1.16 (0.50 to 2.70) .739 1.27 (0.48 to 3.39) .627
Rarely or never — Ref — Ref — Ref
Physical activity intensity†
Moderate (3 to , 6 METs)
Yes 1.83 (0.61 to 5.50) .283 1.95 (0.60 to 6.40) .269 1.42 (0.41 to 4.97) .584
No — Ref — Ref — Ref
Vigorous ($ 6 METs)
Yes 0.62 (0.39 to 0.98) .041 0.51 (0.31 to 0.84) .008 0.41 (0.23 to 0.73) .003
No — Ref — Ref — Ref
NOTE. Bold indicates ORs with P , .05. For the multinomial logistic regression analyses, 37 participants were excluded because of unavailable data for one or more
variables.
Abbreviations: AHO, adverse health outcome; METs, metabolic equivalents; OR, odds ratios; Ref, reference.
*When AHOs were limited to those previously linked to cisplatin (peripheral neuropathy, hearing loss, tinnitus), the OR (per 100 mg/m2) for one (n = 288), two (n = 185),
and three (n = 84) AHOs comparedwith no AHOswere 1.14 (95%CI, 0.87 to 1.49), P = .34; 1.48 (95%CI, 1.11 to 1.97), P = .01; and 1.46 (95%CI, 1.002 to 2.13), P = .05.
†Refer to footnote § in Table 2 for deﬁnition of vigorous and moderate intensity physical activity.
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Table 5. Comparison of Physical Examination Findings, Lipid Proﬁles, and Health Behaviors in 952 Survivors of Cisplatin-Treated Germ Cell Tumors with a Matched
Normative Population
Variable Platinum Study, No. (%) NHANES, No. (%) OR (95% CI)a P b
Total No. of participants 952 (100) 952 (100) — —
Physical examination ﬁnding
Body mass index, kg/m2c
Median (range) 27.5 (18.0-67.0) 27.8 (16.5-66.2) — .446
$ 30 (obese) 294 (31.3) 321 (35.4) 0.94 (0.74-1.20) .037
25 to , 30 (overweight) 404 (43.0) 338 (37.3) 1.23 (0.97-1.55) —
, 25 (normal) 241 (25.7) 248 (27.3) 1.0 (Reference) —
Waist circumference, cmd
Median (range) 94.0 (57.0-190.0) 98.5 (68.0-172.2) — < .001
$ 102 264 (28.2) 355 (40.9) 0.58 (0.47-0.69) < .001
, 102 673 (71.8) 514 (59.2) 1.0 (Reference) —
Lipid proﬁle
Total cholesterol, mg/dLe
Median (range) 202 (119-387) 187 (108-272) — < .001
$ 240 37 (28.2) 10 (7.36) 4.76 (2.25-10.07) < .001
, 240 94 (71.8) 121 (92.4) 1.0 (Reference) —
HDL cholesterol, mg/dLe
Median (range) 55 (15-104) 44 (21-90) — < .001
, 40 20 (15.3) 42 (32.1) 0.38 (0.21-0.70) .001
$ 40 111 (84.7) 89 (67.9) 1.0 (Reference) —
LDL cholesterol, mg/dLe
Median (range) 124 (16-257) 117 (29-206) — .033
$ 160 28 (21.4) 13 (9.9) 2.42 (1.08-5.42) .076
130-159 31 (23.7) 32 (24.4) 1.09 (0.55-2.15) —
100-129 39 (29.8) 49 (37.4) 0.89 (0.48-1.68) —
, 100 33 (25.2) 37 (28.2) 1.0 (Reference) —
Triglycerides, mg/dLe
Median (range) 116 (38-936) 125 (39-376) — .604
$ 150 39 (29.8) 41 (31.3) 0.88 (0.49-1.57) .877
100-149 42 (32.1) 44 (33.6) 0.87 (0.48-1.59) —
, 100 50 (38.2) 46 (35.1) 1.0 (Reference) —
Cardiovascular health outcome
Self-reported high blood pressuref
Yes 155 (16.8) 185 (19.4) 0.83 (0.66-1.06) .141
No 766 (83.2) 766 (80.6) 1.0 (Reference) —
Health behavior
Smoking statusg
Ever 398 (41.8) 503 (52.8) 0.64 (0.54-0.77) < .001
Never 552 (58.2) 449 (47.2) 1.0 (Reference) —
Current: yes 79 (8.5) 286 (30.0) 0.22 (0.17-0.28) < .001
Current: no 848 (91.5) 666 (70.0) 1.0 (Reference) —
No. days per week of alcohol consumptionh
. 2 days 324 (34.1) 186 (23.9) 1.64 (1.33-2.03) < .001
# 2 days 627 (65.9) 591 (76.1) 1.0 (Reference) —
Self-rating of healthi
Excellent 161 (17.0) 103 (12.6) 4.18 (2.77-6.30) < .001
Very good 409 (43.1) 285 (34.8) 3.84 (2.67-5.51) —
Good 331 (34.9) 299 (36.6) 2.96 (2.06-4.26) —
Fair or poor 49 (5.2) 131 (16.0) 1.0 (Reference) —
NOTE. Bold indicates ORs with P, .05. Comparison group was drawn from the 2009-2012 cycle of the NHANES (n = 5,206 men). Controls were matched (1:1) on age,
race, educational level, and fasting status at time of venipuncture (at least 8 hours fasting) to the Platinum Study participant.
Abbreviations: NHANES, National Health and Nutrition Examination Survey; OR, odds ratio.
aBinary logistic regression was used for dichotomous outcomes, and multinomial logistic regression was used for outcomes with more than one level. OR and 95% CI
represent odds of a particular health outcome for participants in the Platinum Study compared with the NHANES normative population.
bBivariate P values derived from the Wilcoxon rank sum test compared median values of outcomes between Platinum Study and NHANES participants. Bivariate
P values derived from x2 tests compared Platinum Study and NHANES participants across all levels of an outcome.
cThere were a total of 58 missing values for body mass index: 13 in the Platinum Study and 45 in NHANES. In addition, four participants in the Platinum Study and ﬁve
NHANES participants were underweight.
dThere were a total of 98 missing values for waist circumference: 15 in the Platinum Study and 83 in NHANES.
eFor the ﬁrst 500 participants in the Platinum Study, wemeasured total serum cholesterol, including HDL and LDL, and triglyceride concentrations with standard assays;
131 (26.2%) participants fasted for at least 8 hours before venipuncture. The reported cholesterol values were restricted to patients who had fasted for at least 8 hours
before venipuncture: 131 participants each in the Platinum Study and in NHANES.
fBlood pressures were self-reported and did not require the use of prescriptionmedications for hypertension. There were a total of 32missing values: 31 in the Platinum
Study and one in NHANES.
gThere were a total of 25 unknown values for current smoking status: 25 in the Platinum Study and 0 in NHANES.
hThere were a total of 176 unknown values for alcohol consumption: one in the Platinum Study and 175 in NHANES.
iThere were a total of 136 unknown values for self-reported health: two in the Platinum Study and 134 in NHANES.
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more TCSs rated their health as excellent, very good, or good
compared with NHANES controls.
In view of our observed associations, health care providers
should promote a healthy lifestyle among TCSs, including tobacco
cessation, physical activity, and weight control. Future prospective
studies should aim to identify high-risk groups who develop
life-threatening conditions that can be reduced by follow-up
management.
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Appendix
Table A1. Deﬁnitions of Adverse Health Outcomes in the Platinum Study
Deﬁnition
Tinnitus: Answered “yes” to any of the following questions: (1) “quite a bit” or “very much” ringing in ears* or (2) ringing or buzzing in ears.†
Hearing impairment: Answered “yes” to any of the following questions: (1) “quite a bit” or “verymuch” for difﬁculty hearing‡; (2) “quite a bit” or “verymuch” reduced
hearing*; (3) problems hearing words, sounds, or language in crowds†; (4) require hearing aid†; (5) complete deafness.†
Peripheral neuropathy: Answered “quite a bit” or “very much” to any of the following questions: (1) tingling in ﬁngers or hands‡; (2) tingling in toes or feet‡;
(3) numbness in ﬁngers or hands‡; (4) numbness in toes or feet‡; (5) shooting/burning pain in ﬁngers or hand‡; (6) shooting/burning pain in toes or feet‡; (7) pain and
tingling in toes or feet*; or (8) pain and tingling in hands or ﬁngers.*
Hypertension and on prescription medication: Answered “Yes” to (1) have you ever been diagnosed with high blood pressure and “Yes, current” to (2) have you ever
taken prescription medications for high blood pressure (including current use).
Hypercholesterolemia and on prescription medication: Answered “yes, current” to the following question: have you ever taken prescription medications for high
cholesterol.
Coronary artery disease: Answered “yes” to any of the following questions: (1) coronary artery disease; (2) angioplasty or stent placement; (3) coronary bypass surgery;
or (4) heart attack or myocardial infarction.
Heart failure: Answered “yes” to heart failure.
Cerebrovascular disease: Answered “yes” to any of the following questions: (1) mini-stroke (transient ischemic attack); (2) stroke; or (3) carotid artery surgery.
Raynaud phenomenon: Answered “quite a bit” or “very much” to any of the following questions: (1) white/cold hands/ﬁngers when it is cold* or (2) white/cold feet/
toes when it is cold.*
Peripheral vascular disease: Answered “yes” to either of the following questions: (1) pain in calf (lower leg) whenwalking (intermittent claudication) or (2) surgery in the
artery in your pelvis or legs (peripheral artery surgery).
Thromboembolic disease: Answered “yes” to either of the following questions: (1) blood clot(s) in leg (deep venous thrombosis) and taking an anticoagulant; or
(2) blood clot(s) in lung (pulmonary embolism) and taking an anticoagulant.
Renal disease: Answered “yes” to kidney disease (renal disease).
Diabetes and on prescription medication: Answered “yes” to either of the following questions: (1) diabetes requiring insulin or (2) diabetes requiring tablets or pills.
Benign thyroid disease: Answered “yes” to either of the following questions: (1) overactive thyroid (hyperthyroidism) or (2) underactive thyroid (hypothyroidism).
Problems with balance/vertigo/dizziness: Answered “yes” to any of the following questions: (1) “quite a bit” or “very much” dizzy when standing up‡ or (2) persistent
dizziness or vertigo.
Hypogonadism with testosterone replacement: Reported using testosterone replacement therapy. Excludes participants who had undergone bilateral orchiectomy.
Erectile dysfunction: Answered “quite a bit” or “very much” to the following question: getting or maintaining an erection.‡
Psychotropic prescription medications for anxiety and/or depression: Reported using anxiolytic, antidepressant, or stimulants.
Obesity: Body mass index $ 30 kg/m2 on clinical evaluation.
*Questionnaire item is from the Scale for Chemotherapy-Induced Long-Term Neurotoxicity (SCIN).21
†Questionnaire item is derived from the hearing handicap inventory by Ventry and Weinstein.22
‡Questionnaire item is from the European Organization for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20.23
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Table A2. Number of Adverse Health Outcomes in 952 Cisplatin-Treated Germ-Cell Tumor Survivors According to Clinical and Sociodemographic Characteristics and
Health Behaviors
Characteristic
No. of Adverse Health Outcomes
0 1-2 3-4 $ 5 Total Patients
No. of patients 194 (20.4) 400 (42.0) 239 (25.1) 119 (12.5) 952 (100)
Clinical characteristic
Age at clinical
evaluation, years
, 30 55 (27.4) 97 (48.3) 36 (17.9) 13 (6.5) 201 (100)
30-39 93 (26.1) 158 (44.2) 81 (22.7) 25 (7.0) 357 (100)
40-49 34 (13.5) 100 (39.7) 79 (31.3) 39 (15.5) 252 (100)
$ 50 12 (8.5) 45 (31.7) 43 (30.3) 42 (29.6) 142 (100)
Cumulative dose of
cisplatin, mg/m2
Median (range) 400 (200-800) 400 (200-600) 400 (198-700) 400 (200-800) 400 (198-800)
# 399 91 (21.8) 172 (41.2) 101 (24.2) 53 (12.7) 417 (100)
$ 400 103 (19.3) 228 (42.6) 138 (25.8) 66 (12.3) 535 (100)
Cumulative dose of
bleomycin, IU
Median (range) 270,000 (90,000-360,000) 270,000 (90,000-540,000) 270,000 (60,000-675,000) 270,000 (84,000-540,000) 270,000 (60,000-675,000)
0 76 (20.6) 160 (43.5) 99 (26.9) 33 (9.0) 368 (100)
. 0-180,000 8 (14.0) 21 (36.9) 18 (31.6) 10 (17.5) 57 (100)
181,000-270,000 86 (22.3) 163 (42.3) 92 (23.9) 44 (11.4) 385 (100)
271,000-360,000 24 (17.6) 53 (39.0) 28 (20.6) 31 (22.8) 136 (100)
. 360,000 0 3 (50.0) 2 (33.3) 1 (16.7) 6 (100)
Retroperitoneal
lymph node
dissection
Yes 93 (20.4) 194 (42.6) 113 (24.8) 55 (12.1) 455 (100)
No* 100 (20.2) 206 (41.7) 124 (25.1) 64 (13.0) 494 (100)
Time from
chemotherapy
completion,
years
, 2 56 (24.9) 102 (45.3) 46 (20.4) 21 (9.3) 225 (100)
2-3 47 (20.9) 93 (41.3) 64 (28.4) 21 (9.3) 225 (100)
4-9 59 (19.8) 138 (46.3) 64 (21.5) 37 (12.4) 298 (100)
$ 10 32 (15.7) 67 (32.8) 65 (31.9) 40 (19.6) 204 (100)
Sociodemographic
characteristic
Race†
White 161 (19.7) 336 (41.1) 211 (25.8) 109 (13.3) 817 (100)
Nonwhite 32 (24.8) 62 (48.1) 26 (20.2) 9 (7.0) 129 (100)
Education‡
Not college
graduate
48 (14.5) 127 (38.5) 96 (29.1) 59 (17.9) 330 (100)
College or
postgraduate
145 (23.8) 267 (43.8) 139 (22.8) 58 (9.5) 609 (100)
Marital status§
Not married 71 (20.1) 159 (44.9) 88 (24.8) 36 (10.2) 354 (100)
Married/living as
married
121 (20.6) 236 (40.3) 147 (25.1) 82 (14.0) 586 (100)
Health behavior
Smoking status
Never smoker 128 (23.2) 243 (44.0) 122 (22.1) 59 (10.7) 552 (100)
Former smoker 60 (18.7) 120 (37.4) 94 (29.3) 47 (14.6) 321 (100)
Current smoker 6 (7.6) 37 (46.8) 23 (29.1) 13 (16.5) 79 (100)
Average number of
alcoholic drinks in
past yearǁ
Rarely or never 27 (14.8) 70 (38.5) 55 (30.2) 30 (16.5) 182 (100)
# 4 per week 100 (22.9) 179 (41.1) 104 (23.9) 53 (12.2) 436 (100)
5 per week to 1 per
day
50 (22.6) 103 (46.6) 51 (23.1) 17 (7.7) 221 (100)
$ 2 per day 15 (13.9) 46 (42.6) 29 (26.9) 18 (16.7) 108 (100)
PA intensity¶
No moderate-
intensity PA
7 (17.9) 12 (30.8) 10 (25.6) 10 (25.6) 39 (100)
Any moderate-
intensity PA (3 to
, 6 METs)
187 (20.5) 388 (42.5) 229 (25.1) 109 (11.9) 913 (100)
(continued on following page)
jco.org © 2017 by American Society of Clinical Oncology
Adverse Health Outcomes Among Testicular Cancer Survivors
Downloaded from ascopubs.org by INDIANA University ACQ DEPT on June 2, 2017 from 134.068.173.193
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Table A3. Prevalence of CVD Risk Factors in Testicular Cancer Survivors Managed with Chemotherapy or Surgery in Selected Clinical Studies
Variable
First Author
Huddart11 Haugnes10
Total No. of patients 632 570
Calendar years of diagnosis 1982-1992 1980-1994
Time period evaluated after diagnosis Entire time period taken together . 2 years
Type(s) of chemotherapy* BEP,PVB,carboplatin-basedregimens,andothers BEP, PVB
Treatment group Chemotherapy Surgery Chemotherapy Surgery
No. of patients 390 242 364 206
Median age at follow-up, years (range) 41 (23-72) 45 (27-76) 49 (31-69) 49 (32-68)
Median follow-up, years (range) 9.7 (0-19.8) 11.4 (0-19.9) 19 (13-28) 19 (13-28)
Prevalence of CVD risk factors,† %
Obesity
Mean BMI (kg/m2) 26.3 26.5 26.7 (6 SD 4.0) 27.7 (6 SD 3.9)
BMI 25-30 (overweight) NA NA NA NA
BMI . 30 (obese) NA NA 17 19
Hypertension 13.3 8.9 26 12
Lipid-lowering medication 0.7 1.7 14 14
Diabetes NA NA 5.4 4.0
Metabolic syndrome NA NA 34 32
Tobacco use: current smoker 24 24 24 19
NOTE. Studies are limited to populations that included at least 300 cisplatin-treated testicular cancer survivors and provided data on CVD risk factors through clinical
evaluation.
Abbreviations: BEP, bleomycin, cisplatin and etoposide; BMI, body mass index; CVD, cardiovascular disease; NA, not available; PVB, cisplatin, vinblastine, bleomycin;
SD, standard deviation.
*Types of chemotherapy regimens are as follows: Huddart et al11: largely BEP (n = 168), PVB (n = 19), and carboplatin-based regimens (n = 138), although number of
cycles of chemotherapy was not reported. Haugnes et al10: largely BEP (n = 160) or PVB (n = 110), although number of cycle of chemotherapy was not reported.
†Deﬁnitions for risk factors are as follows: Huddart et al11: Hypertension: clinical history of hypertension. Lipid-lowering medication: current use of lipid-lowering
medication. Haugnes et al10: Hypertension: use of antihypertensive medication. Lipid-lowering medication: self-reported use of lipid-lowering medication. Diabetes:
prevalent self-reported diabetes and/or fasting serum glucose $ 198 mg/dL. Metabolic syndrome was deﬁned according to Grundy SM, et al: Circulation 109:433-438,
2004. To deﬁne metabolic syndrome, blood samples to measure plasma levels of glucose and lipids were drawn at each general practitioner’s ofﬁce, generally after an
overnight fast.
Table A2. Number of Adverse Health Outcomes in 952 Cisplatin-Treated Germ-Cell Tumor Survivors According to Clinical and Sociodemographic Characteristics and
Health Behaviors (continued)
Characteristic
No. of Adverse Health Outcomes
0 1-2 3-4 $ 5 Total Patients
No vigorous-
intensity PA
36 (12.2) 112 (38.0) 87 (29.5) 60 (20.3) 295 (100)
Any vigorous-
intensity PA
($ 6 METs)
158 (24.0) 288 (43.8) 152 (23.1) 59 (9.0) 654 (100)
NOTE. Data presented as No. (%) unless otherwise noted.
Abbreviations: MET, metabolic equivalent; PA, physical activity.
*Includes three participants for whom retroperitoneal lymph node dissection was not stated.
†Six participants did not provide their race.
‡Thirteen participants had other educational status or did not report.
§Twelve participants did not state their marital status.
ǁFive participants did not state their alcohol consumption status.
¶Refer to footnote § in Table 2 for deﬁnition of vigorous and moderate intensity physical activity.
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